RVMD
AI Execution Plan
Merck (MRK) reportedly in advanced talks to acquire RVMD for ~$30B (~$158/share), per Financial Times, following debunked AbbVie rumors (denied by ABBV). Stock surged 36% this week, hitting new 52-week highs around $123. FDA breakthrough therapy designation for lead asset. Analyst PTs avg $89 (high $147).
Strong Buy rating (TradingView). Price above 50-day MA ($95.10) and making new 52-week highs. Bullish momentum, high volume on rumor days (20M+). RSI likely elevated but trend intact. Support ~$118, resistance broken at $122.
3-Month AI Outlook
Very bullish if MRK acquisition confirms (premium to $158), strong RAS oncology pipeline (RMC-6236 etc.) supports growth. Risk of rumor fade/pullback to $90-100 analyst avg PT if no deal. Overall positive with biotech M&A wave.
Option Chain
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|
Earnings History: RVMD
Revolution Medicines Reports Q3 2025 Financial Results and Clinical Developments
Nov 5, 2025In the third quarter of 2025, Revolution Medicines, Inc. reported a net loss of $305.2 million, compared to a net loss of $156.3 million in the same quarter of the previous year. Revenue was not disclosed. The company's net loss per share was $1.61, based on a weighted average of approximately 189.2 million shares outstanding. The company is winding down global enrollment for the RASolute 302 clinical trial of daraxonrasib in previously treated pancreatic ductal adenocarcinoma (PDAC) and anticipates data readout in 2026. Additionally, they have initiated RASolute 304, a Phase 3 trial for daraxonrasib as an adjuvant treatment for resectable PDAC, while RASolute 303 is set to begin this year for first-line metastatic PDAC. Revolution Medicines reported cash, cash equivalents, and marketable securities totaling $1.93 billion as of September 30, 2025. This includes a recent $250 million royalty monetization from a partnership with Royalty Pharma, with an additional $1.75 billion in future committed capital expected. Research and development expenses for the quarter reached $262.5 million, significantly higher than $151.8 million in Q3 2024, mainly due to increased clinical trial costs and personnel-related expenses. General and administrative expenses also rose to $52.8 million from $24.0 million year-over-year, reflecting expanded operations and legal costs.
Revolution Medicines Reports Q2 2025 Financial Results and Corporate Developments
Aug 6, 2025In the second quarter of 2025, Revolution Medicines reported a net loss of $247.8 million. Revenue was not disclosed for this period. The company's net loss per share was $1.31, compared to a loss of $133.2 million in the same quarter of 2024. During this quarter, the company made significant progress in its clinical trials, particularly with daraxonrasib, which is being tested in two ongoing Phase 3 trials for metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer. They anticipate completing enrollment in the U.S. for the RASolute 302 trial this year and expect to release data in 2026. Additionally, daraxonrasib received FDA Breakthrough Therapy Designation for patients with specific genetic mutations. Revolution Medicines entered into a $2 billion funding agreement with Royalty Pharma, providing the company with flexible financial support for its global development and commercialization goals. As of June 30, 2025, the company had $2.1 billion in cash, cash equivalents, and marketable securities. The company's research and development expenses increased to $224.1 million for the quarter, up from $134.9 million a year earlier, primarily due to higher clinical trial costs and personnel expenses. General and administrative expenses also rose to $40.6 million from $21.7 million the previous year, reflecting increased preparation activities for commercial readiness.
Strategy Overview
Jason Wheel is a systematic, AI‑enhanced trading framework built on probability theory and volatility‑based edge extraction. Designed for the US options market, the system focuses on constructing high‑probability Credit Spread strategies that capture Theta decay while maintaining strict quantitative risk controls to mitigate tail events and support long‑term, stable capital growth.
Rather than relying on directional speculation, the system operates as a closed‑loop asset engine integrating: Macro Risk Control, Multi-dimensional Quantitative Screening, AI-Assisted Decision Making, and Dynamic Position Management.
This architecture enables consistent, rules‑driven execution with an emphasis on risk‑adjusted returns.
Connect with Jason
- Substack: jasonwheel.substack.com
- Email: [email protected]